Navigation Links
Rigel Will Resume Responsibility for Fostamatinib Program
Date:6/3/2013

SOUTH SAN FRANCISCO, Calif., June 4, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). 

In the OSKIRA-2 study of patients inadequately responding to disease modifying anti-rheumatic drugs (DMARDs), fostamatinib in combination with DMARDs showed statistically significant improvements in ACR20 response rates at 24 weeks in both the 100 mg twice daily (bid) group and the group receiving 100 mg bid for four weeks followed by 150 mg once daily (qd) compared to placebo.

In the OSKIRA-3 study of patients inadequately responding to methotrexate (MTX) and a single TNF-alpha antagonist, fostamatinib in combination with MTX showed statistically significant improvements in ACR20 response rates at 24 weeks in the 100 mg bid group, but not in the group given 100 mg bid for four weeks followed by 150 mg qd compared to placebo.

Fostamatinib ACR20 Scores  OSKIRA1

OSKIRA2

OSKIRA3100 mg bid

49%, p<0.001

39.6%, p<0.001

36.2%, p=0.004100 mg bid/150 mg qd

44%, p=0.006

39.6%, p<0.001

27.8%, p=0.168Placebo

34%

24.5%

21.1%Fostamatinib continues to be well tolerated by patients. The safety findings in both the OSKIRA-2 and OSKIRA-3 studies were generally consistent with those observed in the prior OSKIRA-1 study as well as the TASKi Phase 2 program.Based on the totality of the results of the OSKIRA Phase 3 program in patients with RA, AZ has decided that it will not proceed with regulatory filings and will return the rights to the compound to Rigel.

Fostamatini
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
2. Rigel Announces First Quarter 2013 Financial Results
3. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
4. Rigel Announces Participation at Two Investor Conferences
5. Rigel to Present at BIO CEO & Investor Conference
6. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
7. Rigel Announces Third Quarter 2012 Financial Results
8. Rigel to Present at UBS Global Life Sciences Conference
9. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
10. Rigel Announces Second Quarter 2012 Financial Results
11. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Decision Resources, one of the world,s leading research ... that, through 2019, an expanding aging population and increases ... percent annual growth in the chronic obstructive pulmonary disease ... findings from the topic entitled Chronic Obstructive Pulmonary ...
... -- DALLAS, Texas, August 31, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market 2The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 2The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 3The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 4The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 5The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 6The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 7The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 8The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 9
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... The click strand woven ... and durability. Today, the business announces a click ... until Jan. 30, 2015. , Click strand woven ... BambooFlooringChina.com is a well-known brand in the bamboo ... find a reliable bamboo flooring supplier. , “We ...
(Date:12/25/2014)... December 26, 2014 The report “TS-1 ... focuses on the current treatment landscape, unmet needs, current ... TS-1 is an anti-cancer drug which is typically used ... is also used for treating gastric cancer and pancreatic ... potassium. The drug was first approved in 1999 in ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... with tedious record-keepingSEATTLE, March 31 Iccomplish, Inc ... software that takes the tediousness out of corporate ... corporations can remain compliant with corporate reporting laws ... the cost of hiring a corporate attorney. Failure ...
... SHANGHAI, March 31 /PRNewswire-Asia/ -- WuXi AppTec announced today ... the U.S. Food and,Drug Administration (FDA) without the issuance ... non compliance issues after a site inspection. , ... WuXi,s Bioanalytical Services (BAS) was ...
... When beloved miniature Dachshund Frederick ruptured a disc ... and Diane Smith, that he would likely never walk ... dire prognosis, the Smiths sought out alternative treatments, and ... other medical challenges, including lupus, Addison,s disease and encephalitis. ...
... Varian,s VariSeed(TM) 8.0 Offers Advantages in Simplifying Dose ... Va., March 31 Prostate cancer patients have ... that enables improvements in the precision and speed ... Medical Systems (NYSE: VAR ) is ...
... COLUMBIA, Md. and SAN JOSE, Calif., March 31 ... and technologies, today announced that it has entered into ... the embedded computing engine for ... device. After initial delivery of units, Authentidate will have ...
... convenience for physicians, enhances content delivery for health ... ZIXI ), the leader in e-prescribing, ... of ZixCorp,s industry leading e-prescribing application. This ... which leverage the most current versions of industry ...
Cached Medicine News:Health News:Automate Corporate Minutes and Resolutions; Stop IRS Woes Before They Happen 2Health News:WuXi AppTec Bioanalytical Services Unit Passes FDA Inspection 2Health News:Miniature Dachshund's Legacy Inspires YourDogHealth.com to Help Other Canines 2Health News:Miniature Dachshund's Legacy Inspires YourDogHealth.com to Help Other Canines 3Health News:Prostate Cancer Patients in US and Europe Receive Treatments Using Enhanced Seed Prostate Brachytherapy Software 2Health News:Prostate Cancer Patients in US and Europe Receive Treatments Using Enhanced Seed Prostate Brachytherapy Software 3Health News:Eurotech and Authentidate Enter into a Contract for Embedded Computer for Home-Based Medical Device 2Health News:Eurotech and Authentidate Enter into a Contract for Embedded Computer for Home-Based Medical Device 3Health News:Zix Corporation Introduces Powerful New Version of PocketScript 2Health News:Zix Corporation Introduces Powerful New Version of PocketScript 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: